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LDL stimulates mesangial fibronectin production and chemoattractant
expression. Hyperlipidemia has been associated with glomeruloscierosis
and a glomerular monocyte infiltrate in models of progressive renal
insufficiency. The pathogenesis of hyperlipidemia-induced renal injury
remains unknown. We postulated that the effect of hyperlipidemia may
be mediated through LDL-induced activation of mesangial cells, which
have recently been shown to possess LDL receptors. To test this
hypothesis, cultured human mesangial cells were co-incubated with
human LDL. Monolayers treated with LDL demonstrated a greater
level of tissue culture supernatant fibronectin than control mesangial
cells. This correlated with enhanced expression of fibronectin mRNA in
LDL-treated mesangial cells. Additionally, LDL conditioning of me-
sangial cells caused a dose- and time-dependent increase in the expres-
sion of monocyte chemoattractant protein-i mRNA, a monocyte spe-
cific chemotactic factor, as well as an increase in the monocyte
chemotactic activity of mesangial supernatants. Thus, the deleterious
effects of hyperlipidemia on the kidney may be mediated by the
mesangial cell through an increase in production of mesangial matrix
and recruitment of inflammatory cells to the glomerulus.
The final common pathologic manifestation of progressive
renal disease of diverse etiologies is the accumulation of excess
matrix within the glomerular mesangium, resulting in glomeru-
losclerosis [1]. The development of glomeruloscierosis appears
to be influenced by a number of factors, including systemic
hypertension, altered intra-glomerular hemodynamics, and di-
etary protein intake [1, 2]. Recent investigations have demon-
strated that hyperlipidemia (especially hypercholesterolemia) in
experimental animals results in glomerular scarring. Choles-
terol feeding of normal rats or guinea pigs increased plasma
cholesterol levels and caused a spectrum of glomerular lesions
from mesangial matrix accumulation to focal segmental or
global glomerular sclerosis [3—5]. Additionally, the glomeruli of
guinea pigs fed a high cholesterol diet demonstrated a promi-
nent intraglomerular monocyte infiltrate [3]. Hypercholesterol-
emia also appears to be a progression factor in animals with
pre-existing renal lesions, augmenting glomerulosclerosis and
glomerular monocyte infiltration in nephrotic, uninephrecto-
mized, and hypertensive animals [4—6]. Further evidence sup-
porting a role for lipids in renal injury is found in intervention
studies, Administration of lipid lowering agents to animals with
progressive renal disease and hyperlipidemia (such as the obese
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Zucker rat) has been shown to reduce glomerulosclerosis and
proteinuria, and in some cases preserve inulin clearance [7—9].
The relationship between hypercholesterolemia and human
renal disease is less clear, however patients with lecithin:
cholesterol acyltransferase deficiency and hyperlipidemia de-
velop proteinuria, renal failure and show glomerular lipid
deposition and sclerosis on biopsy [10].
Although the pathogenesis of cholesterol augmentation of
renal injury remains unknown, the morphologic similarity be-
tween glomerulosclerosis and atherosclerosis suggests the pos-
sibility of a common mechanism of tissue injury [11]. Athero-
genesis is associated with elevated levels of plasma LDL, and
LDL has been shown to affect endothelial cell biology [12, 13].
Endothelial cells may also oxidatively modify LDL, increasing
its atherogenicity, and causing the lipoprotein to be recognized
by the scavenger receptor rather than the LDL receptor [12,
14]. Other investigators have shown that less extensive oxida-
tion of LDL [resulting in minimally modified (MM)-LDL} yields
a lipoprotein that is a more potent cell activator than native
LDL, but is still recognized by the LDL receptor [13, 15, 16].
Monocytes appear to be involved in this process as well [121;
LDL-treated endothelial cells produce the recently described
monocyte chemotactic factor, monocyte chemoattractant pro-
tein- 1 (MCP-1, 15). MCP-1, which has been found in athero-
sclerotic areas of human blood vessels, may be important in
recruiting inflammatory cells to the developing atherosclerotic
plaque [17].
Recent investigations have shown that rat and human mesan-
gial cells are able to bind and internalize LDL through a
specific, receptor mediated process [18—20]. Like endothelial
cells, mesangial cell activity is altered by LDL. The uptake of
LDL by mesangial cells has been associated with dose-depen-
dent effects on mesangial cell proliferation, secretion of pros-
taglandins, and upregulation of platelet derived growth factor
mRNA [18, 20, 21]. Furthermore, rodent mesangial cells also
appear to express scavenger receptors [20]. The presence of
scavenger receptors on human mesangial cells is controversial;
human cells do not take up chemically modified (acetylated)
LDL [19, 21], but may take up oxidized LDL [22]. These data
provide further evidence for the analogy between atherosclero-
sis and glomerulosclerosis, and suggest that the effects of
hyperlipidemia on the kidney may be mediated through the
actions of LDL on mesangial matrix synthesis and chemoat-
tractant production. To investigate this hypothesis, we mea-
sured mesangial production of the matrix glycoprotein fibronec-
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tin, as well as mesangial expression of monocyte chemoattractant
protein-i (MCP-1), in response to treatment with LDL.
Methods
Lipoprotein preparation
Lipoproteins were isolated from the plasma of fasted normal
volunteers (collected in 3.75 m'vi EDTA) by sequential flotation
using a Beckman L8-55 ultracentrifuge (Beckman Instruments,
Palo Alto, California, USA) according to the method of Have!
et a! [23]. Solid KBr was used for density adjustment [24]. The
low density lipoprotein fraction (LDL, d 1.019 to 1.063 g/ml)
was dialyzed for 24 hours at 4°C against PBS, filter sterilized,
and stored at 4°C under nitrogen. LDL was used within two to
three weeks of isolation. Some samples of sterile LDL were
stored at 4°C in plastic tubes for six to nine months, yielding
minimally modified-LDL (MM-LDL) as described by Berliner
et a! [16]. The protein content of the LDL preparations was
measured using the BCA reagent kit (Pierce, Rockford, Illinois,
USA), and the cholesterol content measured by the cholesterol
esterase/cholesterol oxidase method (Kit #352, Sigma Chemi-
cal Co., St. Louis, Missouri, USA).
After isolation LDL preparations were routinely subject to
agarose gel electrophoresis (Ciba Corning, Palo Alto, Califor-
nia, USA) for 30 minutes at 90 V, and stained with fat red 7B,
to determine baseline electrophoretic mobility and confirm the
absence of VLDL (which binds avidly to the LDL receptor)
contamination [25]. Oxidation of the LDL preparations was
measured as thiobarbituric acid reactive substance (TBARS)
using a previously described spectrophotometric technique
[25], and expressed as nmol malondialdehyde (MDA) equiva-
lents per mg LDL cholesterol. Acutely isolated LDL prepara-
tions demonstrated TBARS levels of 0.26 to 0.66 nmol/mg
cholesterol. Two preparations of MM-LDL stored for six or
nine months demonstrated TBARS levels of 1.8 and 1.64
nmol/mg cholesterol, respectively.
Liposome preparation
In some experiments mesangial cells were treated with cho-
lesterol-rich liposomes to cholesterol-load the cells while by-
passing the LDL receptor. The liposomes were prepared as
described [26] by drying 96 mg cholesterol (Sigma) and 48 mg
phosphatidylcholine in chloroform under nitrogen. Normal sa-
line (12 ml) was added to the dried lipid. This was sonicated for
30 minutes at full power using a 50 watt Ultrasonic Processor
(Cole-Palmer, Chicago, Illinois, USA). The sonicated prepara-
tions were centrifuged at 42,000 x g for 30 minutes, and the
supernatant containing cholesterol-rich liposomes was har-
vested. Aliquots of the aqueous suspension of liposomes were
lipid extracted using the method of Bligh and Dyer [271, and the
cholesterol content of the lipid phase determined spectropho-
tometrically using ferric chloride-H2S04 as the indicator re-
agent [281.
Human mesangial cell culture
Human glomeruli were isolated from donor kidneys unsuit-
able for transplantation by sieving, as previously described [29],
and mesangial cells were obtained as the cellular outgrowths of
collagenase treated glomeruli [30]. Mesangial cells used in this
study were of typical stellate to fusiform morphology, demon-
strated longitudinal actin filaments, did not stain for factor VIII
and cytokeratin [30] excluding endothelial and epithelial con-
tamination, and did not take up acetylated-low density lipopro-
tein [19, 31, 32], excluding macrophage contamination.
Mesangial cells (from 2 donors) were used between passage 5
and 10, and were grown in RPMI- 1640 tissue culture media
(GIBCO, Grand Island, New York, USA), supplemented with
10 mM HEPES, 2 mri L-glutamine, penicillin/streptomycin (100
U/ml) and 20% fetal bovine serum (FBS, all from GIBCO).
Cells were grown in 150 cm2 tissue culture flasks for RNA
isolation (Corning, Corning, New York, USA) or 24-well tissue
culture plates (Linbro, McLean, Virginia, USA) for fibronectin
analysis. The medium of subconfluent cultures was switched to
RPMI-l640 plus 5% Nu-Serum (a defined serum substitute
containing only 25% FBS, Collaborative Research, Bedford,
Massachusetts, USA) for 36 to 48 hours prior to LDL treat-
ment, in order to provide a relatively lipoprotein deficient
environment (the final FBS concentration was thus reduced to
1.25%). Culture in lipoprotein deficient media has been shown
to up-regulate LDL receptors in other cell systems [24]. All
subsequent incubations with LDL were carried out in RPMI-
1640 without serum. Because LDL may increase cell prolifer-
ation at low concentrations and inhibit proliferation at higher
concentrations [20], at the end of each experiment cells were
exposed to 0.05% trypsin in 0.53 mi EDTA (GIBCO) and
counted in a hemocytometer. In 10 experiments performed with
triplicate monolayers exposed to 100 /Lg/ml of LDL for 18 or 24
hours, the average cell counts were 35839 7613 and 42136
6628, respectively, while control monolayers from the same
experiments had cell counts of 36097 7145 and 39534 5981,
respectively. (Additional experiments using an 18 hour expo-
sure to 25 to 50 g/ml of LDL showed similar results.) Thus,
LDL did not significantly affect mesangial cell numbers during
the relatively short duration of exposure used in these studies.
LDL conditioning
Mesangial cells were conditioned with freshly isolated LDL
for various periods of time. In a given experiment simultaneous
control monolayers were treated with tissue culture media
alone. Each condition within an experiment was tested at least
in triplicate. In some experiments mesangial monolayers were
treated with MM-LDL or cholesterol rich liposomes. Cell free
tissue culture supernatants were harvested for subsequent
fibronectin analysis (see below). In some experiments cell
associated fibronectin was obtained by solubilization of washed
monolayers with 1% NP-40 in PBS containing the protease
inhibitors PMSF (0.4 mM), pepstatin (1 g/m1), and leupepin (1
g/m1). The samples were stored at —20°C until assayed for
fibronectin.
Because endotoxin may contaminate LDL preparations, en-
dotoxin levels in LDL samples were measured using the quan-
titative Limulus amebocyte lysate assay (M.A. Bioproducts,
Walkersville, Maryland, USA). The endotoxin levels of the
LDL preparations ranged from undetectable to 32 pg/mg pro-
tein. Since the highest dose of LDL used in these studies was
300 g/ml, the maximum amount of endotoxin present in the
mesangial cultures was approximately 9.7 pg/ml. To exclude a
role for this small quantity of endotoxin in mesangial fibronectin
production, cells were treated with 5 to 1000 pg/mi of E. coli
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endotoxin (0111 :B4, Sigma) for 18 hours under the same con-
ditions used for LDL treatment. Supernatant fibronectin con-
tent was measured. These experiments (N = 2) demonstrated
no difference between fibronectin levels from endotoxin-treated
mesangial cells and control monolayers, suggesting that the
effects of LDL were independent of endotoxin.
Fibronectin measurement
The fibronectin content of mesangial conditioned tissue cul-
ture supernatant was measured using a fibronectin ELISA as
previously described [331. The primary antibody was a specific
rabbit anti-human fibronectin antibody developed in our labo-
ratories [34], and used at a dilution of 1:500. The LDL
preparations did not demonstrate significant fibronectin con-
tamination. When the ELISA was used for cell associated
fibronectin samples, the fibronectin standards were diluted in
PBS-Tween buffer containing 1% NP-40 to compensate for the
effects of NP-40 on the ELISA [30].
Superoxide anion measurement
Experiments were conducted to determine if incubation of
LDL with mesangial cells could induce cellular production of
reactive oxygen species. Superoxide anion was measured by its
ability to reduce ferricytochrome c as previously described [35].
Mesangial cells were incubated with LDL (100 /LgIml) for one
hour at 37°C in the presence of 80 /.LM cytochrome c (Type VI,
Sigma). Basal superoxide anion production was assessed in the
absence of LDL. Non-specific reduction of cytochrome c was
controlled for by the addition of 40 pg/ml of superoxide
dismutase (Sigma) to the cytochrome c solution prior to incu-
bation with the cells. Reduction was measured spectrophoto-
metrically at 550 nm using an extinction coefficient for cyto-
chrome c of 2.1 x i04 M1cm'. Superoxide anion production
was expressed as nmoles of cytochrome c reduced/hr/106 cells.
RNA isolation and Northern blot analysis
Total cellular RNA was isolated from 1 to 3 million mesangial
cells as previously described [36], by homogenizing the cells in
4 M quanidinium thiocyanate (RNAzo1-B, Cinn/Biotex, Friends-
wood, Texas, USA), separating RNA from DNA and protein
with phenol-chloroform extraction, and recovering the RNA by
isopropanol precipitation. RNA samples were washed with
ethanol and quantitated by absorbance at 260 nm. Approxi-
mately 10 g of RNA was fractionated on a 1% agarose gel
containing 1.8% formaldehyde. The gels were stained with
ethidium bromide to confirm uniform RNA loading, and that
there was no degradation during processing. RNA was trans-
ferred to Hybond-N nylon membranes (Amersham, Arlington
Heights, Illinois, USA) by overnight capillary action, and fixed
by baking at 80°C for two hours. The membranes were pre-
hybridized for at least three hours and subsequently hybridized
at 42°C for 20 hours in a solution containing 50% formamide, 5 X
SSC, 1% SDS, 0.2% PVP, 0.2% BSA, 0.2% Ficoll, and 150
tg/ml herring sperm DNA. Membranes were washed twice in
2x SSC plus 0.2% SDS, and then in 0.2x SSC plus 0.1% SDS
at 56°C. Autoradiographs of the blots were made using Kodak
XAR-5 film (Eastman Kodak, Rochester, New York, USA),
and densitometry was performed with an LKB laser densitom-
eter (Pharmacia LKB Biotechnology, Piscataway, New Jersey,
USA). The resulting values were used to calculate relative
amounts of mRNA after correcting for any discrepancies in
RNA loading (see below).
To probe for fibronectin mRNA, a 1.3 kb eDNA to human
fibronectin (ATCC, Rockville, Maryland, USA) was isolated as
the EcoRI fragment from FN771. MCP- 1 mRNA was measured
using a full length cDNA from p-hJE34 (ATCC,37). The probes
were labeled with 32p-dCTP (3000 Ci/mmol) (New England
Nuclear, Boston, Massachusetts, USA), using a random primed
labeling kit (Boehringer-Mannheim, Indianapolis, Indiana,
USA) and the method of Feinberg and Vogelstein [38]. Blots
were subsequently probed for glyceraldehyde-3-phosphate de-
hydrogenase related protein (GAPDP1 probe, ATCC) to nor-
malize the amount of RNA in each lane.
Chemotaxis assay
The chemoattractant activity of LDL-treated mesangial cell
tissue culture supernatants was assessed by a modification of
the method of Falk, Goodwin and Leonard [39], using a 48-well
microchemotaxis assembly (Neuroprobe, Cabin John, Mary-
land, USA) as previously described [31]. Responder cells were
freshly isolated human monocytes purified by the method of
Graziano and Fanger [40]. Typically the preparations were 78%
monocytes (the rest were lymphocytes) with a viability of 95%.
Chemoattractant activity was expressed as the number of
monocytes that migrated through the chemotaxis filter toward
mesangial supernatants after correcting for nonspecific migra-
tion. Nonspecific migration was defined as the number of
monocytes that migrated toward tissue culture media contain-
ing LDL that had not been exposed to mesangial cells. Super-
natants from cells not treated with LDL served as controls.
Statistical analysis
Data are presented as mean standard error, Data were
compared using a two tailed t-test (unpaired unless noted).
Dose-response data involving multiple groups were first evalu-
ated by ANOVA, followed by Dunnett's post-test for experi-
mental groups compared to a single control. A P < 0.05 was
considered significant.
Results
Fibronecrin production by LDL-treated mesangial cells
Cultured human mesangial cells constitutively secrete fi-
bronectin into tissue culture media where it accumulates over
time (Fig. 1). Treatment of mesangial monolayers with LDL
significantly increased supernatant fibronectin content (Fig. 1).
Supernatant fibronectin levels from LDL-conditioned monolay-
ers varied between experiments and cell lines, but were an
average of 1.9- and 1.7-fold higher than control levels at 18 and
24 hours, respectively. The increase in supernatant fibronectin
content of LDL-treated cells was observed up to 30 to 48 hours
after the addition of lipoprotein (data not shown).
Using an 18-hour LDL exposure, a dose-response relation-
ship between LDL and mesangial fibronectin production was
sought. An increase in the supernatant fibronectin level was
seen with as little as 10 /Lg/ml of LDL, and in the illustrated
experiment, appeared to plateau at an LDL concentration of
100 JLg/ml (Fig. 2). The LDL concentration resulting in peak
fibronectin levels was variable and in other experiments peak
production was seen with 25 to 50 ig/ml LDL.
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Fig. 1. Supernatantfibronectin (FN) levels from LDL-treated human
mesangial cell cultures. Mesangial cells were exposed to media alone
(open bars) or media containing LDL, 100 g/ml (solid bars) for the
indicated lengths of time. Conditioned supernatants were harvested,
and fibronectin content measured, as described in Methods. Data were
pooled from 5 to 8 individual experiments each done in triplicate. *p <
0.025, LDL-treated vs. control cells. Data were compared by the paired
t-test.
500
Fig. 2. Dose-dependent increase in the supernatant fibronectin (FN)
level from LDL-treated human mesangial cells. Cultured mesangial
cells were exposed to varying concentrations of LDL for 18 hours prior
to harvesting cell-free supernatants. Corresponding control monolayers
were exposed to media alone (no LDL). Supernatant fibronectin
content was measured. < 0.05, LDL-treated cells vs. control cells.
Data were compared using one-way ANOVA (P < 0.001) followed by
Dunnett's post-test. One of five experiments.
200 100 50 0
Fig. 3. Dose-dependent expression of fibronectin mRNA from LDL-
treated mesangial cells. Northern blot of mesangial RNA after condi-
tioning with the indicated concentrations of LDL (jtg/ml) for 18 hours.
The position of the 28S band is shown. The arrowhead indicates the 8.7
kb fibronectin transcript. (A larger transcript is also present). One of
three representative experiments.
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appeared to be no change in the cell-associated fibronectin level
as a result of LDL treatment.
Fibronectin mRNA expression in mesangial cells
The increased fibronectin content of the supernatants of
mesangial cells treated with LDL suggested that LDL increased
the synthesis of fibronectin. To confirm this, we sought evi-
dence for an LDL-induced increase in fibronectin gene expres-
sion in mesangial cells. Figure 3 is a representative Northern
blot illustrating a dose-dependent increase in mesangial fi-
bronectin mRNA after an 18 hour treatment with LDL. In three
experiments, the increase in fibronectin mRNA levels from
0 50 100 150 200 250 LDL-treated mesangial cells compared to control cells was 1.3-
LDL gig/mI to 2.4- (average = 1.7) fold using 50 g!ml LDL, 1.6- to 2.1-(average = 1.8) fold using 100 ig/ml LDL, and 1.5- to 2.8-
(average = 2.2) fold using 200 pg/mi LDL. Fibronectin mRNA
expression was also dependent on the duration of LDL treat-
Although mesangial cells grown in vitro secrete most of the
fibronectin produced into the media, about 14 to 18% becomes
associated with the cell monolayer and culture surface. Cell-
associated fibronectin was measured after treating mesangial
monolayers with LDL for 18 to 48 hours. The level of cell-
associated fibronectin from cells treated with LDL (100 pg/ml)
for 18 hours was 28 1.5 ng/104 cells; control monolayers
displayed a level of 29 1.6 ng/l04 cells (quadruplicate wells).
After 48 hours of incubation the LDL-treated monolayers had a
fibronectin level of 91 9 ng/l04 cells, while controls had a
level of 82 8 ng!l04 cells (quadruplicate wells). Thus, there
ment, peaking after 18 hours of exposure, and remaining
elevated for at least 30 hours (Fig. 4). The enhanced level of
fibronectin gene expression by LDL-treated cells closely par-
allels the increased fibronectin protein levels found in the
supernatants of these cells.
LDL oxidation and mesangial cell
Oxidized LDL may have greater biologic activity than native
LDL. Furthermore, a variety of cell types have been shown to
oxidize LDL in culture [14, 251. The effects of LDL on
mesangial fibronectin production could potentially be mediated
by oxidized LDL. Thus, experiments were conducted to assess
both the capacity of human mesangial cells to oxidize LDL, and
the effects of MM-LDL on mesangial fibronectin production.
Evidence of LDL modification by mesangial cells was sought
by measuring changes in the electrophoretic mobility of LDL
incubated with mesangial cells. LDL samples which had been
HC
Fig. 4. Time-dependent expression of
fibronectin mRNA from LDL-treated
mesangial cells. Northern blot of mesangial
RNA after conditioning with LDL, 100 g/ml
for the indicated lengths of time. The 8.7 kb
fibronectin transcript is indicated by the
arrowhead. Lane 1: RNA from control
mesangial cells, 18 hour incubation; Lanes 2
to 4: RNA from cells treated with LDL for 4,
18, 30 hours, respectively; Lane 5: RNA from
control mesangial cells, 30 hour incubation.
One of three representative experiments.
incubated with mesangial cells showed a 46% greater mobility
than control LDL (24-hr incubation, 50 jg/ml LDL, distance
migrated from the origin was 11.4 0.9 vs. 7.8 0.4 mm
respectively, N = 3). This migration was not different than that
of concurrently incubated LDL in the absence of cells (11.6
0.9 mm from origin), suggesting that the mild oxidation ob-
served was due to the tissue culture environment rather than
the mesangial cells. It is known, however, that cellular oxida-
tion of LDL may be attenuated if cells are cultured in media
without copper or iron, such as RPMI-l640 [14]. We thus
examined the ability of LDL-treated mesangial cells to elabo-
rate reactive oxygen species, mediators which may be respon-
sible for initiating LDL modification [25, 41]. In three experi-
ments, mesangial cells exposed to LDL produced 10.4 0.9 nm
superoxide anion/hr/106 cells, while control mesangial cells
produced 6.8 0.9 nmlhr/106 cells (P < 0.05). Superoxide anion
is a precursor of other oxygen radicals (such as hydrogen
peroxide) which may also oxidize lipoproteins [41]. LDL-
induced oxygen radical production by mesangial cells may
therefore result in a favorable environment for oxidative mod-
ification of lipoproteins in the glomerulus, enhancing their
biologic activity.
To examine the role of minimally oxidized LDL (presumably
interacting through the LDL receptor) in the induction of
fibronectin synthesis, mesangial cells were incubated with
MM-LDL preparations. Dose-response data are presented in
Figure 5. As illustrated, MM-LDL did increase supernatant
fibronectin content in a dose-dependent fashion. This dose-
response curve was similar to that observed using freshly
isolated LDL (Fig. 2). (The somewhat higher levels of fibronec-
tin in this experiment were likely due to the higher basal levels
of fibronectin produced by these cells, reflecting the variability
of fibronectin production by cells cultured at different times.)
MM-LDL did not appear to be more active in enhancing
fibronectin synthesis by human mesangial cells than the freshly
isolated LDL preparations used in this study.
Cholesterol loading of mesangial cells
Incubation of LDL (150 g cholesterol/ml, 24 hr) with me-
sangial cells resulted in a 76% increase in total cellular choles-
terol (control cells 38.5 5.5 g chol/mg cell protein; LDL-
treated cells, 67.9 5 Lg/mg, N = 3). Since changes in cell
cholesterol content may affect a variety of membrane depen-
dent transport and signal transduction systems [42], it is con-
ceivable that the signal for enhanced matrix synthesis is the
change in cellular lipid content, rather than cell activation via
LDL, 'ug/mI
Fig. 5. Dose-dependent increase in fibronectin production by human
mesangial cells treated with MM-LDL. Cells were incubated with
varying doses of MM-LDL for 18 hours, prior to measuring supernatant
fibronectin content. < 0.05, MM-LDL-treated cells vs. control
monolayers (no LDL). Data were compared using one-way ANOVA (P
< 0.001), followed by Dunnett's post-test. One of two representative
experiments.
the LDL receptor. To study this question we loaded mesangial
cells with cholesterol directly by incubating the cells with
cholesterol-rich liposomes, thus eliminating receptor-mediated
events associated with LDL binding. Exposure of the mesangial
monolayer to 150 p.g/ml of liposome cholesterol for 24 hours
increased total cell cholesterol content from a basal level of5l .8
pg/mg cell protein to 102 16 pg/mg (N = 4). Despite a
liposome-induced increase in cholesterol content similar to that
seen with LDL, there was no increase in the supernatant
fibronectin content from these cholesterol-loaded mesangial
cultures (163 13 ng/l04 cells vs. a control supernatant content
of 152 3 ngIl0 cells; triplicate monolayers, one of two
representative experiments). This implies that simply lipid-loading
the cell is not sufficient to cause enhanced fibronectin expression.
MCP-1 expression in mesangial cells
Monocyte accumulation is a feature of both experimental
glomeruloscierosis and atherosclerosis, and may be important
in the induction of tissue injury [3, 12, 13]. Recent studies
investigating monocyte recruitment to atherosclerotic plaques
have demonstrated the presence of MCP- 1 in these lesions [171.
We thus investigated the possibility that LDL could induce
MCP-1 expression in cultured human mesangial cells. As shown
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Fig. 6. Time and dose-dependent expression
of MCP-l mRNA from LDL-treated
mesangial cells. A. Northern blot of
mesangial RNA after 18 hours of conditioning
with the indicated concentrations of LDL (g/
ml). The MCP-l mRNA band is shown. C =
RNA from control mesangial cells. One of
two representative experiments. B. Northern
blot of mesangial RNA after incubation with
LDL, 75 gIml, for the indicated lengths of
time (hours). C represents RNA from control
cells; L represents RNA from LDL-treated
cells.
in Figure 6, MCP-1 mRNA increased in a time and dose-
dependent fashion in response to LDL. This increase in MCP-l
message was associated with increased monocyte chemoattrac-
tant activity in the supernatants of LDL-treated mesangial cells.
Enhanced monocyte migration was seen toward supernatants
from mesangial cells conditioned with LDL (75 tg/ml) for six
hours (17.5 0.3 cells/hpf vs. a migration of 10.9 0.5 cells/hpf
toward control supernatants, P < 0.001). In five additional
experiments, after 18 hours of LDL (40 to 50 jg/m1) treatment,
net monocyte migration was 2.7 0.5-fold greater toward these
supernatants than supernatants from control mesangial cells (P
<0.04, paired t-test).
Discussion
Experimentally induced hypercholesterolemia in animals
with progressive renal disease is associated with enhanced
glomerular matrix accumulation, infiltration by monocytes, and
glomerulosclerosis [3—fl]. The pathogenetic relationship be-
tween elevated lipid levels and glomerular injury remains
unknown. The recent demonstration that glomerular mesangial
cells possess LDL receptors [18—20] suggests that the effects of
hyperlipidemia may be mediated by an interaction between
LDL and mesangial cells. Evidence from the present study
supports this hypothesis. The data may be summarized as
follows: (1) incubation of mesangial cells with LDL (or MM-
LDL) increased the fibronectin content of the mesangial condi-
tioned supernatants in a time and dose-dependent fashion; (2)
increased supernatant fibronectin levels correlated with an
increase in fibronectin mRNA levels; (3) enhanced fibronectin
production was not simply a function of lipid-loading mesangial
cells, but was dependent on the lipoprotein being present,
suggesting a requirement for LDL receptor occupancy; (4) LDL
treatment of mesangial cells up-regulated MCP-1 mRNA ex-
pression, and increased the monocyte chemoattractant activity
of mesangial cell conditioned supernatants.
The association of an LDL-induced increase in supernatant
fibronectin levels with an LDL-induced increase in fibronectin
mRNA strongly implies a direct effect of LDL on fibronectin
synthesis, although decreased fibronectin degradation could
also be a contributing factor. Measurement of cell-associated
fibronectin demonstrated that there was no redistribution of
fibronectin from the cell-associated compartment to the super-
natant, also supporting increased fibronectin synthesis.
Because LDL appears to stimulate the production of the
matrix glycoprotein fibronectin, it is appealing to speculate that
other components of the mesangial matrix may be similarly
affected, thus accounting for the progression of glomerular
scarring in a hyperlipidemic environment. In other cell culture
systems where the effects of LDL on the synthesis of matrix
components such as collagen and proteoglycans have been
examined, some studies demonstrated an increase in synthesis
[431, while others showed no effect [44]. It will therefore be
important to directly document changes in mesangial collagen,
laminin, and proteoglycan synthesis in response to LDL for a
full understanding of the role of this lipoprotein in matrix
accumulation.
The effects of LDL on fibronectin production were not
reproduced by lipid loading the cells with liposome cholesterol.
These data suggest that the activation of mesangial cells by
LDL is due to LDL receptor occupancy, although we cannot
exclude the presence of other potential mediators of matrix
regulation within the LDL fraction of human serum. Addition-
ally, while the present study did not specifically address the
mechanism of action of LDL, two possibilities are apparent.
LDL may act directly to increase fibronectin synthesis, or it
may cause mesangial cells to release other factors that may
regulate mesangial matrix synthesis in an autocrine fashion.
These mediators could include platelet-derived growth factor
(PDGF), which appears to be up-regulated in mesangial cells by
LDL [21], or transforming growth factor-/3 (TGF-13), a peptide
that may be regulated by PDGF [451 and is known to enhance
mesangial matrix synthesis [46].
Oxidized LDL is postulated to play an important role in the
pathogenesis of atherosclerosis [12, 13]. Accumulating evi-
dence suggests that LDL may undergo oxidation in vivo, which
may be of pathologic importance [13]. However, the present
study did not find the minimally oxidized preparations of LDL
(MM-LDL) to be more active than freshly isolated LDL in
stimulating mesangial fibronectin synthesis. We cannot exclude
the possibility that other oxidized forms of LDL may be more
potent activators of mesangial cells. Indeed, exposure of LDL
to the tissue culture environment alone resulted in oxidation
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which may have been important in activating fibronectin pro-
duction. Additionally, we did not observe augmented oxidation
of LDL upon exposure to mesangial cells under the experimen-
tal conditions used in this study. In contrast, other investigators
have shown oxidation of human LDL by rodent mesangial cells
when incubations were carried out in media containing copper
and iron [471. We did, however, show that LDL stimulated
superoxide anion production by mesangial cells. Since oxygen
radicals are potential mediators of lipoprotein oxidation [25,
41], these data suggest a possible mechanism of mesangial
oxidation of LDL within the glomerulus.
LDL may also indirectly play a role in the development of
glomeruloscierosis by inducing mesangial production of the
chemoattractant MCP- 1, a potential signal for glomerular
monocyte recruitment. A variety of monocyte-derived growth
factors and cytokines have been shown to increase glomerular
cell proliferation and matrix synthesis, processes that are
important in progressive glomerular disease. For example,
PDGF and interleukin-1 promote mesangial cell proliferation
[45, 48]. Extracellular matrix production is stimulated by
TGF-/3 (mesangial cells) and interleukin- 1 (glomerular epithelial
cells) [46, 49]. Infiltrating monocytes may thus participate in
glomerular sclerosis through the elaboration of such factors.
The in vivo relevance of the current observations remains to
be determined. Given the fact that the mesangium is separated
from the plasma only by a fenestrated endothelium, mesangial
cells are continuously exposed to LDL levels which may be
tenfold higher than those used in our cell culture system. Thus,
a low level of mesangial LDL receptor expression in vivo could
be expected [24). To reconcile the in vitro observation of
enhanced mesangial matrix synthesis with the (probable) low
level of mesangial LDL receptor expression in vivo, it is
attractive to speculate that injury to the kidney may result in an
up-regulation of mesangial LDL receptors. This effect could
conceivably be mediated by growth factors or cytokines that
are expressed by mesangial cells or infiltrating leukocytes
during glomerulopathic processes. For example PDGF, a factor
which may be elaborated during glomerular injury [45], has
been shown to induce LDL receptor expression in mesenchy-
mal cells [501. LDL could then function as a progression factor,
activating mesangial cells that had been primed by such growth
factors.
In summary, LDL treatment of cultured human mesangial
cells results in the enhanced accumulation of the matrix glyco-
protein fibronectin in the tissue culture supernatants. LDL also
induced an increase in the mesangial expression of MCP- 1
mRNA and the monocyte chemoattractant activity of mesangial
cell conditioned supernatants. These results suggest that LDL
may promote glomerulosclerosis through the stimulation of
mesangial matrix synthesis, and indirectly by recruiting mono-
cytes to the glomerulus which could then alter glomerular
structure and function. These studies provide further evidence
supporting a role of lipids in renal injury.
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